NCT02653625View on ClinicalTrials.gov

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 14, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Cenicriviroc 150 mg

One tablet of CVC 150 mg once daily taken with food in the morning.

Trial Locations (9)

10029

Icahn School of Medicine, New York

33136

University of Miami, Miami

92037

Scripps Clinic, La Jolla

94115

Sutter Health, California Pacific Medical Center, San Francisco

95817

University of California, Davis Medical Center, Sacramento

T2N 4Z6

University of Calgary, Liver Unit, Calgary

T6G 2X8

University of Alberta, Zeidler Ledcor Centre, Edmonton

R3E 3P4

University of Manitoba, Winnipeg

M5G 2C4

Toronto University Health Center, Toronto

All Listed Sponsors
lead

Tobira Therapeutics, Inc.

INDUSTRY

NCT02653625 - PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter